Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape
Jason R. Brown, Vadim S. Koshkin
Topics & Concepts
MedicinePembrolizumabMetastatic Urothelial CarcinomaOncologyInternal medicineUrothelial carcinomaImmunotherapyCancerBladder cancerBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers